Investigating long-term diabetes effects after COVID-19 infection
Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus
The University of Texas Health Science Center at San Antonio · NCT05867017
This study looks at how having COVID-19 might lead to diabetes and related health issues in people who didn't have diabetes before.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 213 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | The University of Texas Health Science Center at San Antonio (other) |
| Locations | 1 site (San Antonio, Texas) |
| Trial ID | NCT05867017 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the long-term effects of COVID-19 infection on individuals without a prior history of diabetes. It will assess various diabetes-related measures, including glycemic control, beta cell function, insulin secretion, and insulin sensitivity among hospitalized and non-hospitalized COVID-19 patients, as well as individuals who have not contracted the virus. The research seeks to establish a connection between COVID-19 and the development of diabetes and related metabolic issues over time.
Who should consider this trial
Good fit: Ideal candidates include individuals who have had COVID-19, either hospitalized or treated as outpatients, as well as those who have not contracted the virus but were seen in clinics during the same timeframe.
Not a fit: Patients with a history of diabetes prior to SARS-CoV-2 infection or those who have taken diabetes medications before the infection may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the long-term health risks of COVID-19, particularly regarding diabetes development, which may lead to improved patient management and preventive strategies.
How similar studies have performed: Other studies have indicated potential links between COVID-19 and metabolic disturbances, but this specific investigation into long-term diabetes effects is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Body Mass index (BMI) \< 40 kg/m2 Exclusion Criteria: * History of diabetes prior to SARS-CoV-2 infection * Took medications used to treat diabetes prior to SARS-CoV-2 infection * History of myocardial infarction or stroke within 6 months * History of major organ system disease prior to COVID-19 infection
Where this trial is running
San Antonio, Texas
- Texas Diabetes Institute - University Health System — San Antonio, Texas, United States (RECRUITING)
Study contacts
- Principal investigator: Ralph DeFronzo, MD — University of Texas Health Science Center San Antonio
- Study coordinator: Marzieh Salehi, MD
- Email: salehi@uthscsa.edu
- Phone: (210) 567-6691
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: COVID-19, Diabete Mellitus, Glycemic control, Long term medical effects of COVID-19, Blood glucose control, Insulin sensitivity